Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc. (NEUP) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · NEUP · as of Sep 30, 2025
Ownership Breakdown
15
Institutional Holders
▲ 6 vs Q2
$2.30M
Total Inst. Value
▲ $1.04M vs Q2
5.40M
Shares Outstanding
freeFloat 77.47%
195,338
13F Shares Held
▲ 17,375 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
NEUP largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ADVISORSHARES INVESTMENTS LLC pharmaceutical preparations | 58.6K | 2.61% | 2.61% | $690.46M | Nov 5, 2025 | ▼ 9.2K |
PROSPERITY WEALTH MANAGEMENT, INC. pharmaceutical preparations | 29.8K | 1.33% | 1.33% | $351.64M | Nov 14, 2025 | ▲ 75 |
DIADEMA PARTNERS LP pharmaceutical preparations | 21.5K | 95.51% | 95.51% | $252.92M | Nov 14, 2025 | NEW |
VANGUARD GROUP INC pharmaceutical preparations | 20.9K | 93.27% | 93.27% | $247.00M | Nov 7, 2025 | NEW |
MILLENNIUM MANAGEMENT LLC pharmaceutical preparations | 18.3K | 81.60% | 81.60% | $216.10M | Nov 14, 2025 | NEW |
JANE STREET GROUP, LLC pharmaceutical preparations | 15.7K | 69.76% | 69.76% | $184.74M | Nov 14, 2025 | NEW |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 13.0K | 57.78% | 57.78% | $153.01M | Nov 12, 2025 | NEW |
MERCK & CO., INC. pharmaceutical preparations | 10.0K | 44.64% | 44.64% | $118.22M | Nov 12, 2025 | — held |
PERSISTENT ASSET PARTNERS LTD pharmaceutical preparations | 4.9K | 21.85% | 21.85% | $57.87M | Jan 15, 2026 | NEW |
UBS GROUP AG pharmaceutical preparations | 2.2K | 9.65% | 9.65% | $25.56M | Nov 13, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
2
Increased
+91 shares9
New Positions
first time holders1
Decreased
−9.2K shares3
Sold Out
fully exitedNet shares change (top 50)
9.1K
+91 / −9.2K
Net new holders
+7
9 new / 3 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
NEUP insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
4
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Wilson David Ian director | Jan 20, 2026 | Award | 8,537 | — | — | 15.4K | Form 4 ↗ |
Davies Peter Miles Winston director | Jan 20, 2026 | Award | 8,537 | — | — | 15.3K | Form 4 ↗ |
Fisher Alan director | Jan 20, 2026 | Award | 17,073 | — | — | 30.7K | Form 4 ↗ |
Ryan Jane director | Jan 20, 2026 | Award | 8,537 | — | — | 15.6K | Form 4 ↗ |
Lynx1 Capital Management LP 10 percent owner | Oct 21, 2025 | Purchase | 639,110 | $5.14 | $3.28M | 875.3K | Form 4 ↗ |
Papapetropoulos Spyros President and CEO | Aug 27, 2025 | Award | 34,559 | $8.27 | $285.8K | 74.1K | Form 4 ↗ |
Papapetropoulos Spyros President and CEO | Apr 16, 2025 | Award | 27,000 | $5.16 | $139.3K | 39.5K | Form 4 ↗ |
Papapetropoulos Spyros President and CEO | Apr 16, 2025 | Award | 270,000 | $5.16 | $1.39M | 282.5K | Form 4 ↗ |
Davies Peter Miles Winston director | Apr 16, 2025 | Award | 6,783 | — | — | 6.8K | Form 4 ↗ |
Ryan Jane director | Apr 16, 2025 | Award | 6,783 | — | — | 7.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Neuphoria Therapeutics Inc. (NEUP) is primarily owned by institutional investors, who hold approximately 3.6% of total shares outstanding. Company insiders own approximately 22.53%, while retail and public investors account for the remaining 73.85%.
The largest institutional shareholder of Neuphoria Therapeutics Inc. is ADVISORSHARES INVESTMENTS LLC, holding approximately 58,563 shares — equal to 2.61% of outstanding shares — as of September 30, 2025.
A total of 15 institutional investors currently hold NEUP stock, with a combined institutional value of approximately $2,303,036 as of the most recent 13F filing period.
Frequently asked questions
NEUP ownershipNeuphoria Therapeutics Inc. (NEUP) is primarily owned by institutional investors, who hold approximately 3.6% of shares. The largest shareholder is ADVISORSHARES INVESTMENTS LLC with a 2.61% stake. Company insiders hold 22.53%. Data sourced from SEC Form 13F as of September 30, 2025.